Filtered By:
Cancer: Ovarian Cancer

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 759 results found since Jan 2013.

Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy.
Abstract With the discovery of RNA interference technology, small-interfering RNA (siRNA) has emerged as new powerful tool for gene therapy because of its high targeting specificity and selectivity. However, one of the limitations to successful gene therapy is the inability to monitor delivery of genes and therapeutic responses at the targeted site. Hence, a combinatorial approach of gene therapy with molecular imaging has been crucial in optimizing gene therapy. Recent advances in nanotechnology have made tremendous efforts to develop multifunctional nanoparticles that contain imaging and therapeutic agents toget...
Source: Current Pharmaceutical Design - October 23, 2015 Category: Drugs & Pharmacology Authors: Tekade RK, Maheshwari RG, Sharma PA, Tekade M, Chauhan AS Tags: Curr Pharm Des Source Type: research

Effect of siRNA-induced Atg7 gene silencing on the sensitivity of ovarian cancer SKOV3 cells to cisplatin.
Authors: Zhang X, Wang LL, Wang B, Liu HL, Zhang J, Li YH, Wang LH Abstract Ovarian cancer is one of the most common types of gynecological malignant tumors. A proclivity for, or the development of chemoresistance severely affects treatment efficacy for ovarian cancer. Herein we found that as concentrations of cisplatin (DDP) used in SKOV3 cells increased, expression of intracellular reactive oxygen species (ROS) increased as did amounts of proteins of Beclin-1 and Autophagy-Related Gene 7 (Atg7) whereas in contrast, expression of P62 protein decreased gradually. Expression of Atg7 protein in SKOV3 cells in the siR...
Source: American Journal of Translational Research - June 10, 2020 Category: Research Tags: Am J Transl Res Source Type: research

Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer
CONCLUSIONS: Our results suggest that the inhibition of TIMP-2 by siRNA and CRISPR/Cas-9 modulate the expression of MMP-2 and MMP-14 and reprogram ovarian cancer cells to facilitate proliferation and invasion. Distinct disparities in in vitro chemosensitivity and growth in 3D culture, and differences in tumour burden and invasion to proximal organs in a mouse model imply that selective suppression of TIMP-2 expression by siRNA or CRISPR/Cas-9 alters important aspects of metastasis and chemosensitivity in ovarian cancer.PMID:36585738 | DOI:10.1186/s12935-022-02838-x
Source: Cancer Control - December 30, 2022 Category: Cancer & Oncology Authors: Ruth M Escalona Simon Chu Elif Kadife Jason K Kelly George Kannourakis Jock K Findlay Nuzhat Ahmed Source Type: research

Notch3‐specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel‐resistant ovarian cancer cells
Notch signaling plays an important role in ovarian cancer chemoresistance, which is responsible for recurrence. Gamma‐secretase inhibitor (GSI) is a broad‐spectrum Notch inhibitor, but it has serious side effects. The efficacy of Notch3‐specific inhibition in paclitaxel‐resistant ovarian cancers was assessed in this study, which has not yet been evaluated relative to GSI. To analyze the effect of Notch3‐specific inhibition on paclitaxel‐resistant ovarian cancers, we compared cell viability, apoptosis, cell migration, angiogenesis, cell cycle, and spheroid formation after treatment with either Notch3 siRNA or GS...
Source: Molecular Carcinogenesis - July 24, 2015 Category: Molecular Biology Authors: Haeyoun Kang, Ju‐Yeon Jeong, Ji‐Ye Song, Tae Heon Kim, Gwangil Kim, Jin Hyung Huh, Ah‐Young Kwon, Sang Geun Jung, Hee Jung An Tags: Research Article Source Type: research

SiRNA and epigenetic aberrations in ovarian cancer
Hamed Mirzaei, Foad Yazdi, Rasoul Salehi, Hamid Reza MirzaeiJournal of Cancer Research and Therapeutics 2016 12(2):498-508 Ovarian cancer has the most noteworthy lethal rate around gynecologic malignancies, and it is also considered as the fourth most frequent cancer in the woman in world. Two most critical barriers to treatment of ovarian malignancy are absence of early diagnostic markers and advancement of drug resistance after therapy, especially in advanced stages. Various epigenetic changes have been recognized in ovarian cancer. Recent progresses in our understanding of molecular pathogenesis of ovarian malignancy h...
Source: Journal of Cancer Research and Therapeutics - July 24, 2016 Category: Cancer & Oncology Authors: Hamed Mirzaei Foad Yazdi Rasoul Salehi Hamid Reza Mirzaei Source Type: research

Intraperitoneal Nanotherapy for Metastatic Ovarian Cancer Based on siRNA-Mediated Suppression of DJ-1 Protein Combined with a Low Dose of Cisplatin
Herein, we report an efficient combinatorial therapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. DJ-1 protein modulates, either directly or indirectly, different oncogenic pathways that support and promote survival, growth, and invasion of ovarian cancer cells. To evaluate the potential of this novel therapy, we have engineered a cancer-targeted nanoplatform and validated that DJ-1 siRNA delivered by this nanoplatform after intraperitoneal injection efficiently downregulates the DJ-1 protein in metastatic ovarian cancer tumors and ascites.
Source: Nanomedicine : Nanotechnology, Biology, and Medicine - April 7, 2018 Category: Nanotechnology Authors: Canan Schumann, Stephanie Chan, Jess A. Millar, Yuliya Bortnyak, Katherine Carey, Alex Fedchyk, Leon Wong, Tetiana Korzun, Abraham S. Moses, Anna Lorenz, Delany Shea, Olena Taratula, Oleh Khalimonchuk, Oleh Taratula Source Type: research

Surface-engineered polyethyleneimine-modified liposomes as novel carrier of siRNA and chemotherapeutics for combination treatment of drug-resistant cancers.
We report the development of novel liposomal formulations surface-modified with a low molecular weight, branched polyethyleneimine (bPEI)-lipid conjugate for use as an alternative to PEG. The formulations had very good stability characteristics in ion- and protein-rich mediums. Protein adsorption onto the liposomal surface did not interfere with the cellular interaction. bPEI-modified liposomes (PEIPOS) showed enhanced association with three different cell lines by up to 75 times compared to plain or PEGylated liposomes and were without carrier toxicity. They also penetrated the deeper layers of 3D spheroids. Encapsulating...
Source: Drug Delivery - April 3, 2019 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

In vivo delivery of siRNA targeting vasohibin‐2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer
This article is protected by copyright. All rights reserved.
Source: Cancer Science - September 1, 2013 Category: Cancer & Oncology Authors: Takahiro Koyanagi, Yasuhiro Suzuki, Yasushi Saga, Shizuo Machida, Yuji Takei, Hiroyuki Fujiwara, Mitsuaki Suzuki, Yasufumi Sato Tags: Original Article Source Type: research

Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo
Highlights: Abstract: SKOV3/DDP cells urgently require an efficient therapy to improve drug resistance. Here we show a critical role for cisplatin combined with gene therapy, using transfection of a p53 gene/MDM2-siRNA plasmid, in improving cisplatin sensitivity of SKOV3/DDP cells with a strong inhibition of tumor cell growth in vitro and in vivo. The effects may be associated with enhancement of intracellular platinum accumulation via decreased MDR1/P-gp and improvement of apoptotic resistance via increased P53, PUMA and NOXA expression. The combined therapy may efficiently inhibit cell invasion and migration via deceased...
Source: Cancer Letters - December 2, 2013 Category: Cancer & Oncology Authors: Junlian Gu, Yufeng Tang, Yanan Liu, Hua Guo, Yue Wang, Lu Cai, Yang Li, Bo Wang Tags: Research Articles Source Type: research

Preclinical and clinical development of siRNA-based therapeutics.
Abstract Discovery of RNA interference, first in plants and C. elegans and later in mammalian cells, led to the emergence of a transformative view in biomedical research. Knowledge of the multiple actions of non-coding RNAs has truly allowed viewing DNA, RNA and proteins in novel ways. Small interfering RNAs (siRNAs) can be used as tools to study single gene function both in vitro and in vivo and are an attractive new class of therapeutics, especially against undruggable targets for the treatment of cancer and other diseases. Despite the potential of siRNAs in cancer therapy, many challenges remain, including rapi...
Source: Advanced Drug Delivery Reviews - February 6, 2015 Category: Drugs & Pharmacology Authors: Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G Tags: Adv Drug Deliv Rev Source Type: research

Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models
Epithelial ovarian cancer (EOC) is the most deadly gynecologic malignancy on account of its late stage at diagnosis and frequency of drug resistant recurrences. Novel therapies to overcome these barriers are urgently needed. TWIST is a developmental transcription factor reactivated in cancers and linked to angiogenesis, metastasis, cancer stem cell phenotype, and drug resistance, making it a promising therapeutic target. In this work, we demonstrate the efficacy of TWIST siRNA (siTWIST) and two nanoparticle delivery platforms to reverse chemoresistance in EOC models.
Source: Nanomedicine : Nanotechnology, Biology, and Medicine - November 23, 2016 Category: Nanotechnology Authors: Cai M. Roberts, Sophia Allaf Shahin, Wei Wen, James B. Finlay, Juyao Dong, Ruining Wang, Thanh H. Dellinger, Jeffrey I. Zink, Fuyuhiko Tamanoi, Carlotta A. Glackin Tags: Original Article Source Type: research

Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer
Publication date: Available online 14 April 2018 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Sophia A. Shahin, Ruining Wang, Shirleen I. Simargi, Altagracia Contreras, Liliana Parra, Louise Qu, Wei Wen, Thanh Dellinger, Juli Unternaehrer, Fuyuhiko Tamanoi, Jeffrey I. Zink, Carlotta A. Glackin TWIST protein is critical to development and is activated in many cancers. TWIST regulates epithelial-mesenchymal transition, and is linked to angiogenesis, metastasis, cancer stem cell phenotype, and drug resistance. The majority of epithelial ovarian cancer (EOC) patients with metastatic disease respond wel...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - April 15, 2018 Category: Nanotechnology Source Type: research

Role of Increased n-acetylaspartate Levels in Cancer
Conclusion: These findings indicate that the NAA pathway has a prominent role in promoting tumor growth and represents a valuable target for anticancer therapy. Altered energy metabolism is a hallmark of cancer (1). Proliferating cancer cells have much greater metabolic requirements than nonproliferating differentiated cells (2,3). Moreover, altered cancer metabolism elevates unique metabolic intermediates, which can promote cancer survival and progression (4,5). Furthermore, emerging evidence suggests that proliferating cancer cells exploit alternative metabolic pathways to meet their high demand for energy and to accumul...
Source: JNCI - January 26, 2016 Category: Cancer & Oncology Authors: Zand, B., Previs, R. A., Zacharias, N. M., Rupaimoole, R., Mitamura, T., Nagaraja, A. S., Guindani, M., Dalton, H. J., Yang, L., Baddour, J., Achreja, A., Hu, W., Pecot, C. V., Ivan, C., Wu, S. Y., McCullough, C. R., Gharpure, K. M., Shoshan, E., Pradeep, Tags: Article Source Type: research